강미경 (Massachusetts General Hospital / Harvard Medical School)님 | 한빛사연구자 > 한빛사

Massachusetts General Hospital / Harvard Medical School

CV File

최종업데이트 2024.02.28.

- ( 현재 등록 진행중입니다. )
- 송자연(한국생명공학연구원, 성균관대학교, Massachusetts General Hospita)
- 강미경(Massachusetts General Hospital / Harvard Medical School, 고려대학교)
- 차백동(한국기계연구원)
- 이학호(Massachusetts General Hospital / Harvard Medical School)
- 강태준(KAIST, 한국생명공학연구원)
Self-amplifying CRISPR-based one-pot ultrasensitive testing for rapid SARS-CoV-2 and its variant detection
- Biosens. Bioelectron., Available online 15 May 2026 | https://doi.org/10.1016/j.bios.2026.118814
- 2026-05
- 한빛사논문
- 강미경(Massachusetts General Hospital / Harvard Medical School)
Sustained and Localized Drug Depot Release using Radiation-Activated Scintillating Nanoparticles
- Adv. Mater., Feb 23 2024, | https://doi.org/10.1002/adma.202312326
- 2024-02
- 바이오·의료융합
- 한빛사논문
Nanovesicle-mediated targeted delivery of immune checkpoint blockades to potentiate therapeutic efficacy and prevent side effects
- Adv. Mater., First published: 28 December 2021 | https://doi.org/10.1002/adma.202106516
- 2021-12
- 바이오·의료융합
- 한빛사논문
Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy
- Adv. Mater., First published: 12 September 2021 | https://doi.org/10.1002/adma.202103258
- 2021-09
- 바이오·의료융합
- 한빛사논문
T-cell-mimicking nanoparticles for cancer immunotherapy
- Adv. Mater., First published: 18 August 2020 | https://doi.org/10.1002/adma.202003368
- 2020-08
- 바이오·의료융합
- 한빛사논문
M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors
- ACS Nano, Publication Date (Web): August 22, 2018 | DOI: 10.1021/acsnano.8b02446
- 2018-08
- 바이오·의료융합
- 한빛사논문

연구자 ID

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기